Released Nov 3, 2026, after the close
10-Q filed Nov 3, 2026, 34 days after period end · 0001628280-26-069501
Corcept’s third quarter 2026 revenue was $340.5 million, compared to $256.1 million in the second quarter of 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $340.47M | $207.64M | $182.55M | $123.60M |
| Net Income | $126.78M | $19.67M | $47.21M | $31.38M |
Corcept Therapeutics Inc · CIK 1088856 · Engraved from SEC EDGAR
| EPS Diluted | $1.01 | $0.16 | $0.41 | $0.28 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Net income was $126.8 million, or $1.01 per diluted share, compared with $19.7 million, or $0.16 per diluted share, in third quarter 2025.¶2¶3
The company reiterated its 2026 revenue guidance of $1.1 – $1.2 billion.¶4
Cash and investments were $662.3 million at September 30, 2026, after the acquisition of $43.7 million of common stock under the stock repurchase program in the third quarter.¶5¶6
The BELLA Part A Phase 2 trial in platinum-resistant ovarian cancer reported median PFS of 7.2 months and ORR of 59 percent in 95 patients.¶7